The Institute for Clinical and Economic Review has received industry backlash over changes to its value-assessment process it proposed in June. The changes, if implemented, would lower the threshold ranges for cost-effectiveness down to $50,000 to $100,000 a year, a net drop of $50,000 at each end of the range. The outgoing ICER president Steve Pearson noted that these changes are not going to be immediately implemented and are still under consideration.
According to Paul Schlosser, “The National Pharmaceutical Council (NPC), which counts 20 biotechs and pharma companies as members, said in a statement that ICER should not lower its cost-effectiveness threshold, saying the research ICER cited is from a study that relies on “unvalidated assumptions.””
To read more, click here.
(Source: Endpoints News, July 6th, 2023)